A federal district court March 28 ruled in favor of generic drugmakers that patents related to the Warner Chilcott Co. and Hoffmann-La Roche Inc. bone drug Actonel were invalid (Warner Chilcott Co. v. Teva Pharm. USA, Inc., D. Del., 1:08-cv-00627-LPS, 3/28/14).
In consolidated litigation, the plaintiffs alleged that defendants’ proposed generics infringed patents on their drug.
Judge Leonard P. Stark of the U.S. District Court for the District of Delaware found the patents-in-suit invalid due to obviousness.
Motions for Summary Judgment.
In September 2008, the plaintiffs filed a complaint alleging that Teva Pharmaceuticals USA’s abbreviated new drug ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.